Default company panoramic image

Confluence Pharmaceuticals LLC

Restoring Hope and Unlocking Potential: A drug that treats core social and communication impairments caused by Autism & Fragile X Syndrome.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Indianapolis, IN, USA
  • Currency USD
  • Founded June 2010
  • Employees 0
  • Website

Company Summary

Confluence is developing a clinically discovered, novel therapeutic treatment for patients suffering life-long impairments caused by Autism and Fragile X Syndrome. No drug exists today in this $13 billion market. We have patented IP, human data, 3 potential biomarkers, confirmed FDA plan, and U.S./E.U. Orphan designations. This is a capital efficient development model that presents a low risk, a high return opportunity in a 2-3 year window.


  • Default avatar
    Steven L. Johns

    Steve has built a reputation as an Innovator & Leader through a variety of diverse experiences acquired in a number of successful start-ups and early stage companies. His career includes 10 years in Banking / Financial Management and 15 years in his own business ventures. His business experience extends in these key areas; Strategic Planning, Building Management Teams, Transforming Business Models, Mergers & Acquisitions, and Capital Formation.

  • Default avatar
    Boyd W. Sturdevant, Jr

    Boyd has been associated with the mental health industry most of his 40 year career. He developed and recently sold Indiana’s largest freestanding Employee Assistance business and pioneered per-capita mental health managed care programs with employers. Boyd brings a depth of working knowledge in the areas of commercializing mental health services, engaging mental health advocate/consumer groups, measuring perception of treatment outcomes.

  • Default avatar
    Craig A. Erickson, MD
    Lead Scientific Advisor

    Dr. Erickson is Chief of the Fragile X Treatment Center at Cincinnati Children's Hospital, Adjunct Asst Professor of Psychiatry, Former Chief of the Christian Sarkine Autism Treatment Center and Fragile X Research/Treatment Center at Riley Hospital, Indiana University School of Medicine. He is currently directing research projects using acamprosate with patients and is involved with other national FXS and ASD related research.

  • Default avatar
    Timothy F. Parshall
    Vice President of Corporate Affairs

    Mr. Parshall’s experience spans over 25 years in global healthcare strategy, marketing and business development. Mr. Parshall has been a Director of Strategic Marketing at both Guidant and Eli Lilly & Company. He led product marketing and technology acquisition efforts on a national and international level. His current focus is on the development of start-up and early-stage revenue companies in both the medical device and biotechnology fields

  • Default avatar
    Sharon Rosenzweig-Lipson, PhD
    Vice President of Research

    Dr. Rosenzweig-Lipson has over 18 years experience developing compounds for Psychiatric and Neurologic indications in the pharmaceutical industry (American Cyanamid – American Home Products – Wyeth – Pfizer). She has successfully led teams from the earliest exploratory studies through to Phase II Proof of Concept Trials. In 2011, she founded IVS Pharma Consulting LLC to bring her expertise in in screening strategies, in vivo models, translation


  • Default avatar

Previous Investors

  • Default avatar
    High network individuals